2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS) | Synapse
August 26, 2022Open Access
2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS)
Puntos clave
Cardiac implantable electronic devices are critical in managing cardiovascular complications.
Patients aged 65-74 years and those with chronic myeloid leukaemia face unique cardiac risks.
Guidelines include advanced cardiac magnetic resonance techniques for better diagnosis and management of cardiac issues in cancer patients. Their implementation may improve patient outcomes during cancer treatment.
Resumen
65-74 years, Sex category (female) CIED Cardiac implantable electronic device CML Chronic myeloid leukaemia CMR Cardiac magnetic resonance COMPASS-CAT Prospective COmparison of Methods for thromboembolic